Deviating from clinical practice: Pharmacokinetics of Chinese materia medica faces a substantial challenge
Authors:
Open Access
- 1 July 2020
- journal article
- research article
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 127, 110191
Abstract
No abstract availableKeywords
Funding Information
- ational Natural Science Foundation of China (81773891)
- Beijing Excellent Talent Project (2018000021223TD09, DFL20190702))
- National Great New Drugs Development Project of China (2017ZX09301-040)
This publication has 11 references indexed in Scilit:
- Gut microbiota, a new frontier to understand traditional Chinese medicinesPharmacological Research, 2019
- Combination of chemical fingerprinting with bioassay, a preferable approach for quality control of Safflower InjectionAnalytica Chimica Acta, 2018
- CONSORT Extension for Chinese Herbal Medicine Formulas 2017: Recommendations, Explanation, and ElaborationAnnals of Internal Medicine, 2017
- Use of in vitro bioassays for assessing botanicalsCurrent Opinion in Biotechnology, 2014
- Discovery of safety biomarkers for realgar in rat urine using UFLC-IT-TOF/MS and 1H NMR based metabolomicsAnalytical and Bioanalytical Chemistry, 2013
- Drug Interactions with Herbal MedicinesClinical Pharmacokinetics, 2012
- Gut microbiota: a potential new territory for drug targetingNature Reviews Drug Discovery, 2008
- A culture in the balanceNature, 2007
- Therapeutic wisdom in traditional Chinese medicine: a perspective from modern scienceTrends in Pharmacological Sciences, 2005
- History of Chinese Medicine: Being a Chronicle of Medical Happenings in China from Ancient Times to the Present Period.1933